Relmada Therapeutics (RLMD) Total Current Liabilities (2012 - 2026)

Relmada Therapeutics (RLMD) has 15 years of Total Current Liabilities data on file, last reported at $12.9 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 146.43% year-over-year to $12.9 million in Q1 2026; TTM through Mar 2026 was $12.9 million, a 146.43% increase from a year earlier, with the FY2025 full-year figure at $6.4 million, down 37.52% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $12.9 million, up from $6.4 million in the prior quarter.
• Over the last five years, Total Current Liabilities for RLMD reached as high as $20.8 million in Q3 2022 and fell as low as $5.1 million in Q2 2025.
• Historically, Total Current Liabilities has averaged $10.8 million across 5 years, with a median of $10.3 million in 2024.
• Across the five-year window, Total Current Liabilities slumped 59.46% in 2023 and jumped 146.43% in 2026, its largest moves.
• Year by year, Total Current Liabilities stood at $12.5 million in 2022, then slipped by 2.2% to $12.2 million in 2023, then decreased by 15.61% to $10.3 million in 2024, then plunged by 37.52% to $6.4 million in 2025, then soared by 100.48% to $12.9 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $12.9 million in Q1 2026, $6.4 million in Q4 2025, and $5.2 million in Q3 2025.